Kwality Pharmaceuticals Ltd · BSE:KPL
Kwality Pharmaceuticals — Investor Presentation (June 2025)
19 slides from Kwality Pharmaceuticals's investor presentation, Jun 5, 2025
Slide 1: BSE cover letter: Investor Presentation FY25
CIN No. L24232PB1983PLC005426 GST No. . 03AAACK64 58M1ZB Phone 91.83588208 62 (Accounts) :91-8558820863 (Admin.) ® D.L. No. 1800-OSP, 1804-B LE. Code No. 1293001210 s R, KWALITY PHARMACEUTICALS LIMITED | o.use: o sersoiats sotoses ile : 91+ 14052314 ramesh@kwalitypharma.com Regd. Office: Village Nag
Slide 2: Kwality Pharmaceuticals Ltd Investor Presentation FY25
Kwality Pharmaceuticals Ltd India’s fastest growing manufacturer of complex injectables INVESTOR PRESENTATION FY25
Slide 3: Disclaimer
A DISCLAMER Some of the statements made in this presentation are forward-looking statements and are based on the current beliefs, assumptions, expectations, estimates, objectives and projections of the directors and management of Kwality Pharmaceutical Limited about its business, the industry and ma
Slide 4: Table of Contents
TABLE OF CONTENTS Title Page Company Overview KPL at a Glance Journey so far Promoters Profile Plants of KPL Differentiated Capabilities Revenue Split Key markets by sale Complex Injectables development Biologics R&D and Manufacturing excellence Financial Metrics Growth strategy and Financials
Slide 5: Company Overview
COMPANY OVERVIEW Kwality Pharma : A legacy of quality and growth For over 40 years, Kwality Pharma has been a trusted name in the healthcare sector, synonymous with unparalleled growth and reliability. We are driven by a customer centric vision, committed to delivering high quality products. JASSUR,
Slide 6: Kwality Pharma at a Glance
KWALITY PHARMA AT A GLANCE Manufacturing Excellence Established Dedicated History ‘Workforce Product Specialization ! @Q) Development and supply of affordable Founded in 1983, with 40+ Ov 700 employees, including experience. 80+ in R&D Complex Injectables R&D Capabilities “ In-house research and dev
Slide 7: More Than Three Decade Legacy of Experience and Trust
MORE THAN THREE DECADE LEGACY OF EXPERIENCE AND TRUST 2018 2022 2024 Manufacturing Facility Upgradation Established Beta lactam Unit Initiated Preclinical programme for Migrated to Main Board of KPL 1'st Biologics Journey so far... PIC/s GMP for Injectable facility BSE € Successful approval and 1983
Slide 8: Promoters Profile
PROMOTERS PROFILE Mr. Ramesh Arora, Managing Director Arespected leader in the pharmaceutical industry, Ramesh Arora has played a pivotal role in transforming Kwality Pharma Ltd into a globally trusted brand. With decades of experience, he drives strategic growth and mentors the next generation of l
Slide 9: Plants of KPL: General Block, Beta Lactam, Biologics
General Block Beta Lactam Biologics Unit 2 e Unit § zrra (o Oral Solids — Tab/Capsule, Suppositories Oral Solids — Tab/Capsule Drug Product — PFS Capabilities Ointments/Creams, Oral Liquids Powder for Injection Drug Substance — Sterile Liquid Dental Cartridges Dry Syrup Injectables (Vials/Ampoules/P
Slide 10: Plants of KPL: Cephalosporins and Oncology
Cephalosporins Oncology Unit 3 Unit 4 Oral Solids — Tab/Capsule Oral Solids — Tab/Capsule Injectables (Vials) (Liquid/Lyophilized) Powder for Injection Dry Syrup Tablets — 380 Million Capsules — 38 Million Tablets — 205 Million Capsules — 31 Million Liquid Injection (Non peptide) —47 Million Powder
Slide 11: Differentiated Capabilities
DIFFERENTIATED CAPABILITIES Liposomal Pegylated Injectables &£ W Tissue Targeting - "~ Sustained Drug Release Intracellular Targeting -- 1"~ Peptide-based Injections Necaond Increased Exposure Time - - Polymeric Microspheres Drug Solubilization ~ *~ In-situ Forming Depots / i Emulsion Technology ® F
Slide 12: Revenue Split
REVENUE SPLIT REVENUE (INRCR) 777777 370| Growing with CAGR (3Yrs) — 21.4% FY23 FY24 Facility Wise Sales Break Up Segment Wise Sales Break Up Unit Wise Sales Break Up “‘ = Injectable - ‘ = Oral Solids = Oral Liquids = External Preparations = Oph/Otics . . = Oral Powders 10 = Amritsar = Himachal mUni
Slide 13: Geographic Segmentation
GEOGRAPHIC SEGEMENTATION Latam GCC/MENA Africa 1 1 / . ! Asia South and Central ,’ America \‘ \ Domestic \ \ \ \ Russia/CIS \ \ ’ \ \ \ H EU \ K : \\ I i Africa | ! Asia % of sales 11
Slide 14: Championing the Art of Complex Injectable Development
® Championing the art of Complex Injectable Development Micro- ‘ — N Nano- Liposomal @ particle #) Pe-gylation Few of them are.... API Partner Propofol Emulsion EU Manufacturer Filed —20+ Octreotide Long Acting Release Indian Manufacturer Filed — 10+ 10 mg/ ml (KPL Strategic Partner) Approved — 10+
Slide 15: Biologics
BIOLOGICS KPL Erythropoietin Programme 1 KPL Biological Snapshot 1 rent Status Clinical Clinical Clinical 1 — Studies Stu 1 Approval 1 KPL 001 - Erythropoietin POC established Secure regulatory 1 Completed Q3 FY 2026 2000 IU, 4000IU, 10000IU Stability studies available approval 1 Characterization St
Slide 16: Striving for Excellence
STRIVING FOR EXCELLENCE Research Excellence Manufacturing Excellence Our R&D division is at the forefront of Pharmaceutical All manufacturing units are equipped with Innovation. With a team of experienced scientist, we focus state of the art equipment and adhering to on developing innovative drug de
Slide 17: Financial Metrics
FINANCIAL METRICS Revenue (INR CR) EBITDA (INR CR) 370 1A% CAGRS 80 60 ! I 23 Fr2a FY25 FY23 FY24 FY25 PAT (INR CR) EPS 38.36 oo 85 A0 CP\G‘.’T»-#ZA"" 2276 18.16 FY23 24 FY25 FY23 24 FY25 15
Slide 18: KPL Growth Strategy and Financials
KPL Growth strategy and Financials Revenue from 251 307 370 % Revenue Target Operations Aiming for 500 crores in revenue Total Expenses 190 241 290 - 7' EBITDA Margins EBITDA 60 66 80 O |Projecting margins between 22— Finance cost 6 10 10 0, 2SS v e Initiaci Depreciation 15 20 18 @ trategic " itiati
Slide 19: Thank You
THANK YOU Kwality Pharmaceuticals Limited Head Office Address: 6™ Milestone, Majitha Road, Amritsar-143601, Punjab, India Email: ujjvalseth@kwalitypharma.com cs@kwalitypharma.com info@kwalitypharma.com
Kwality Pharmaceuticals — Investor Presentation (June 2025) on 6ix